Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$39.34M+6.8%-$32.23M+34.1%-$36.93M+34.5%-$43.27M-5.5%-$42.21M-34.0%
$6K-60.0%$13K-13.3%$15K+36.4%$16K+77.8%$15K+87.5%
$6.55M+79.6%$5.29M+68.6%$5.84M+86.1%$4.55M+58.5%$3.65M+66.4%
-$39.47M+13.2%-$37.89M+43.3%-$28.87M+42.5%-$30.17M-0.1%-$45.49M-138%
-$44.94M+51.6%-$103.49M-224%-$150.51M-289%-$42.88M-654%-$92.88M-66.0%
$24.27M-87.2%$96.7M+107,346%$295.19M$9.83M$189.28M+62.9%
-$60.14M-218%$115.81M+294%-$63.22M$50.92M+23.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Mineralys Therapeutics, Inc. generate?
Mineralys Therapeutics, Inc. (MLYS) generated -$136.4M in operating cash flow over the trailing twelve months.
Where does Mineralys Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.